Duker Jay S. 4
4 · EyePoint Pharmaceuticals, Inc. · Filed Jul 11, 2025
Insider Transaction Report
Form 4
Duker Jay S.
DirectorPresident and CEO
Transactions
- Exercise/Conversion
Common Stock
2025-07-10+16,667→ 17,653 total - Tax Payment
Common Stock
2025-07-10$11.06/sh−7,688$85,029→ 9,965 total - Exercise/Conversion
Restricted Stock Units
2025-07-10−16,667→ 16,667 totalExercise: $0.00→ Common Stock (16,667 underlying)
Holdings
- 99,165(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
- [F2]These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
- [F3]The restricted stock units vests in three ratable annual installments beginning July 10, 2024.